Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants. - Wikidata - awgldk - TriplyDB

Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.

Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.

http://www.wikidata.org/entity/Q34986049

about

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective Effectiveness of drug therapies to treat or prevent respiratory syncytial virus infection-related morbidity.Matrix Metalloproteinase-9 Mediates RSV Infection in Vitro and in Vivo Cost, causes and rates of rehospitalization of preterm infants.Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)Recent advances in the development of subunit-based RSV vaccines.Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants.Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants: a note of caution.Effectiveness of palivizumab prophylaxis in infants and children in Florida

P2860

Q26830864-67CF4BA5-F262-4194-B50A-A2A71D288D45 Q35548189-73E11E46-01C9-4950-A1DE-656509AFFB89 Q36076225-12CD439D-2400-41DF-B6CF-E0859BCB2794 Q36918637-9058B706-8BBE-4645-B0D8-7AE74CD970F4 Q37290618-703299E4-C68D-4365-83BE-714F932C3E5B Q38617302-6BF78A54-FA4E-4ADF-BBC0-34923966F40C Q45375474-6FFD55E2-8180-49BD-9FCF-F530D28E748B Q45708826-9A27F4A7-167B-484C-AA17-5AFB6B487F72 Q57830092-6A7F0ED4-E668-4B85-9CBD-E4CC00AF40EA

P2860

Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.

http://www.wikidata.org/entity/Q34986049

description

2002 nî lūn-bûn

@nan

2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.

@ast

Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.

@en

Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.

@nl

type

label

Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.

@ast

Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.

@en

Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.

@nl

prefLabel

Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.

@ast

Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.

@en

Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.

@nl

P1433

Q34986049-E834DC28-0BB2-48AB-A8E8-9DA6A93368E6

P1476

Q34986049-131A68EB-D630-4E81-BD2B-6E85214790E8

P2093

Q34986049-20685C6D-3FFE-4CE9-8739-178AC58802B1

Q34986049-2531AD15-8672-4FEC-BC25-A6A454A7D40A

Q34986049-4A70D099-FFC4-4D82-9E34-93AA7FF5EE90

Q34986049-509C23CB-8B8F-495F-9FE2-708A1C94A94F

Q34986049-55FDFD29-ECCC-4ABE-A58D-9F658FFBC39C

Q34986049-6303FAB1-E334-4EE1-9ED3-72FAA0B85B84

Q34986049-D90CD89E-6379-4713-92F6-2D2FD970E394

Q34986049-E60A4CDA-F4F4-4BBF-9A90-B491AEFCB355

P2860

Q34986049-651E6564-918A-4A71-9F40-C2943DD9D94C

Q34986049-8926C677-20E2-4F7A-821D-84425057BFCD

Q34986049-D17D00EC-CF43-49D6-B0C3-E03B65F8B54E

Q34986049-D7E5AB03-D061-4A91-BE29-9CDC70A914E3

Q34986049-E0F92C44-CD35-4E08-9417-BA75C3DFEE6A

Q34986049-F198409F-BB8C-40AC-9AB2-7796EDCD015F

Q34986049-F27C71DD-2B28-4684-9CD5-EFC3E94DDFA8

Q34986049-F457FCF7-1EA5-442F-8033-D20DA3273CAF

P304

Q34986049-4ED146D5-EC61-42BB-B835-EF2DF604A41C

P31

Q34986049-41B2E185-2BC7-4322-816F-F7A2165E7302

P356

Q34986049-DB711F46-4759-4B1A-8C7A-E366566EA1B1

P433

Q34986049-A94D18AA-E3E2-4B8B-8E45-05622B89F753

P478

Q34986049-D3B06859-FAAE-4994-82B9-FFC1DF106CCC

P577

Q34986049-A8EBB53E-DD86-43BB-B64A-65D6B0830BFB

P698

Q34986049-EF0828F2-8877-4382-B8E1-D39F7B5F34DC

P356

J.1440-1754.2002.00057.X

P1433

Journal of Paediatrics and Child Health

P1476

Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.

@en

P2093

Broadbent R

http://www.w3.org/2001/XMLSchema#string

Byrnes CA

http://www.w3.org/2001/XMLSchema#string

Grimwood K

http://www.w3.org/2001/XMLSchema#string

Lennon DR

http://www.w3.org/2001/XMLSchema#string

Mildenhall L

http://www.w3.org/2001/XMLSchema#string

Richardson V

http://www.w3.org/2001/XMLSchema#string

Rowley S

http://www.w3.org/2001/XMLSchema#string

Vogel AM

http://www.w3.org/2001/XMLSchema#string

P2860

Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.

Immunoprophylaxis of respiratory syncytial virus disease.

Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group.

Preventing respiratory syncitial virus bronchiolitis.

Palivizumab and RSV prevention.

Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost.

Cost-effectiveness of palivizumab in New Zealand.

When do infants need additional inspired oxygen? A review of the current literature.

P304

550-554

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1440-1754.2002.00057.X

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P577

2002-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12410864

http://www.w3.org/2001/XMLSchema#string